Last reviewed · How we verify
Inhaled loxapine 10 mg
At a glance
| Generic name | Inhaled loxapine 10 mg |
|---|---|
| Also known as | ADASUVE 10 mg, ADASUVE, Staccato Loxapine 10 mg, Inhaled Staccato Loxapine 10 mg |
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
- Staccato Prochlorperazine Single Dose PK Study (PHASE1)
- Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication (PHASE1)
- Staccato Loxapine Thorough QT/QTc Study (PHASE1)
- Staccato Loxapine Pulmonary Safety in Healthy Volunteers (PHASE1)
- Staccato Prochlorperazine Thorough QT/QTc (PHASE1)
- Staccato Loxapine Single Dose PK (PHASE1)
- Staccato Loxapine in Agitation (Proof of Concept) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled loxapine 10 mg CI brief — competitive landscape report
- Inhaled loxapine 10 mg updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI